GlassScriptPhysician profile
Marney Goldstein
NPI 1598895260
$6,003.68
in general payments reported to CMS, 2019-2025
27 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $648 · 2021: $464 · 2022: $372 · 2023: $765 · 2024: $1,017 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,531.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.30 | 2019-2025 | |
| Janssen Biotech, INC. | $827.10 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $692.81 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Lilly USA, LLC | $322.89 | 2024-2025 | Omvoh, Zepbound |
| Gilead Sciences, INC. | $305.42 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $272.30 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $267.91 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $253.62 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $219.41 | 2019-2025 | |
| Genzyme Corporation | $158.25 | 2025 | |
| Phathom Pharmaceuticals, INC. | $156.19 | 2024-2025 | Voquezna |
| Celgene Corporation | $155.94 | 2021-2023 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Madrigal Pharmaceuticals | $107.26 | 2024-2025 | Resmetirom, Rezdiffra |
| Ironwood Pharmaceuticals, INC | $92.32 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $84.82 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $70.75 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $55.48 | 2021-2023 | |
| Allergan, INC. | $48.76 | 2019 | |
| Evoke Pharma, INC. | $44.91 | 2020-2023 | Gimoti |
| Fresenius Kabi USA, LLC | $37.72 | 2023 | |
| Redhill Biopharma INC. | $32.37 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $29.66 | 2025 | Givlaari |
| Shire North American Group INC | $19.16 | 2019 | |
| Shionogi INC | $18.66 | 2019 | |
| Merck Sharp & Dohme LLC | $17.50 | 2019 | |
| Daiichi Sankyo INC. | $17.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marney Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.